American Cancer Society guideline for the early detection of prostate cancer, 2026
21 affiliations
- 1University of Iowa Carver College of Medicine Iowa City Iowa USA
- 2University of Virginia School of Medicine Charlottesville Virginia USA
- 3Biostatistics Program Fred Hutch Cancer Center Seattle Washington USA
- 4Duke Cancer Institute Center for Onco‐Primary Care Duke University Durham North Carolina USA
- 5Radiation Oncology Brown University Health Brown School of Public Health Providence Rhode Island USA
- 6Biostatistics Brown School of Public Health Providence Rhode Island USA
- 7Division of Geriatrics, Department of Medicine University of California‐San Francisco San Francisco California USA
- 8Cancer Prevention and Control Fox Chase Cancer Center Philadelphia Pennsylvania USA
- 9University of Minnesota School of Public Health Minneapolis Minnesota USA
- 10Masonic Cancer Center Minneapolis Minnesota USA
- 11Columbia Memorial Health Hudson New York USA
- 12Prostate Health Education Network, Inc. Hudson New York USA
- 13Health Policy and Management Columbia University New York New York USA
- 14Biostatistics and Epidemiology University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA
- 15Obstetrics and Gynecology Tufts University and Tufts Medical Center Boston Massachusetts USA
- 16Department of Radiation Oncology David Geffen School of Medicine University of California‐Los Angeles Los Angeles California USA
- 17Cancer Health Economics Research Program University of California‐Los Angeles Los Angeles California USA
- 18Medicine (Biostatistics) Massachusetts General Hospital Boston Massachusetts USA
- 19Center for Early Cancer Detection American Cancer Society Atlanta Georgia USA
- 20Cancer Surveillance American Cancer Society Atlanta Georgia USA
- 21American Cancer Society Atlanta Georgia USA
Abstract
The goal of prostate cancer screening is to reduce morbidity and mortality through the early detection of clinically significant disease. Accumulating evidence shows that prostate‐specific antigen (PSA)‐based screening significantly reduces prostate cancer mortality and advanced‐stage diagnosis, and approaches to reduce harms associated with screening are increasingly being used. The ACS conducted a systematic review and commissioned a modeling study to evaluate PSA‐based screening strategies, and concluded that the benefits of screening outweigh the harms. Before initiating screening, clinicians should ensure that patients are informed about the benefits, limitations, and harms of screening; the potential follow‐up evaluations of elevated PSA levels; and the expectation that low‐risk cancers will initially be managed with active surveillance. The ACS recommends biennial screening from ages 50‐69 years for average‐risk men (i.e., non‐Black men without a family history of prostate cancer). Annual screening from ages 45‐69 years is recommended for Black men. Annual screening from ages 45–69 years is recommended for non‐Black men with a strong family history (i.e., multiple first‐degree relatives diagnosed with prostate cancer at any age or one diagnosed before age 65 years). Biennial screening from ages 45‐69 years is recommended for non‐Black men with a single first‐degree relative diagnosed at age 65 years or older. For men ages 70–74 years, the balance of benefits and harms is uncertain, and individualized decision making is recommended. The ACS recommends further evaluating men ages 45–69 years with PSA levels ≥3.0 ng/mL and men ages 70–74 years with PSA levels ≥6.5 ng/mL. Most men who have elevated PSA levels confirmed on repeat testing should be offered magnetic resonance imaging and/or a validated biomarker test to guide biopsy decisions. Screening is not recommended for men with a life expectancy <10 years and should be discontinued at age 75 years.
Related
- Prostate‐specific antigen‐based screening for prostate cancer: A systematic review to inform an American Cancer Society guideline
- Noninvasive respiratory support for adult patients with acute respiratory failure: an official American Thoracic Society Clinical Practice Guideline
- American Epilepsy Society/Congress of Neurological Surgeons Epilepsy Surgery Clinical Practice Guideline.
- Expanded American Cancer Society Lung Cancer Screening Eligibility and Predicted Risk
- Personalized genomic landscape of prostate cancer in African American men reveals novel drivers and therapeutic opportunities
BibTeX
@article{hoffman2026american,
title = {{American Cancer Society guideline for the early detection of prostate cancer, 2026}},
author = {Richard M. Hoffman and Andrew M. D. Wolf and Ruth D. Etzioni and Kevin C. Oeffinger and Sana Raoof and Louise C. Walter and Charnita Zeigler‐Johnson and Timothy R. Church and Christopher K. Jones and Artie L. Shelton and Elena B. Elkin and Carmen E. Guerra and Rebecca B. Perkins and Ya‐Chen Tina Shih and Steven J. Skates and Roman Gulati and Hormuzd A. Katki and Tyler B. Kratzer and Deana Manassaram‐Baptiste and William L. Dahut and Robert A. Smith},
journal = {Ca},
year = {2026},
month = nov,
doi = {10.3322/caac.70112},
url = {https://doi.org/10.3322/caac.70112},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - American Cancer Society guideline for the early detection of prostate cancer, 2026
AU - Richard M. Hoffman
AU - Andrew M. D. Wolf
AU - Ruth D. Etzioni
AU - Kevin C. Oeffinger
AU - Sana Raoof
AU - Louise C. Walter
AU - Charnita Zeigler‐Johnson
AU - Timothy R. Church
AU - Christopher K. Jones
AU - Artie L. Shelton
AU - Elena B. Elkin
AU - Carmen E. Guerra
AU - Rebecca B. Perkins
AU - Ya‐Chen Tina Shih
AU - Steven J. Skates
AU - Roman Gulati
AU - Hormuzd A. Katki
AU - Tyler B. Kratzer
AU - Deana Manassaram‐Baptiste
AU - William L. Dahut
AU - Robert A. Smith
PY - 2026
DA - 2026/11/12
JO - Ca
DO - 10.3322/caac.70112
UR - https://doi.org/10.3322/caac.70112
AB - The goal of prostate cancer screening is to reduce morbidity and mortality through the early detection of clinically significant disease. Accumulating evidence shows that prostate‐specific antigen (PSA)‐based screening significantly reduces prostate cancer mortality and advanced‐stage diagnosis, and approaches to reduce harms associated with screening are increasingly being used. The ACS conducted a systematic review and commissioned a modeling study to evaluate PSA‐based screening strategies, and concluded that the benefits of screening outweigh the harms. Before initiating screening, clinicians should ensure that patients are informed about the benefits, limitations, and harms of screening; the potential follow‐up evaluations of elevated PSA levels; and the expectation that low‐risk cancers will initially be managed with active surveillance. The ACS recommends biennial screening from ages 50‐69 years for average‐risk men (i.e., non‐Black men without a family history of prostate cancer). Annual screening from ages 45‐69 years is recommended for Black men. Annual screening from ages 45–69 years is recommended for non‐Black men with a strong family history (i.e., multiple first‐degree relatives diagnosed with prostate cancer at any age or one diagnosed before age 65 years). Biennial screening from ages 45‐69 years is recommended for non‐Black men with a single first‐degree relative diagnosed at age 65 years or older. For men ages 70–74 years, the balance of benefits and harms is uncertain, and individualized decision making is recommended. The ACS recommends further evaluating men ages 45–69 years with PSA levels ≥3.0 ng/mL and men ages 70–74 years with PSA levels ≥6.5 ng/mL. Most men who have elevated PSA levels confirmed on repeat testing should be offered magnetic resonance imaging and/or a validated biomarker test to guide biopsy decisions. Screening is not recommended for men with a life expectancy <10 years and should be discontinued at age 75 years.
SN - 0007-9235
SN - 1542-4863
ER -